JANUARY 24, 2023 — Glioblastoma multiforme (GBM) is an aggressive brain cancer associated with the worst overall survival rates among all human cancers. Only 65% of GBM patients live one year past diagnosis and only 12% live five years. The late senators Ted Kennedy and John McCain both died of GBM on the same day (August 25) nine years apart (Kennedy in 2009; McCain in 2018).
A San Antonio research team is working to give GBM survivors new hope. Scientists from the Department of Chemistry at The University of Texas at San Antonio (UTSA), Department of Obstetrics and Gynecology at UT Health San Antonio, and Mays Cancer Center at UT Health San Antonio are making compounds to hopefully one day treat GBM tumors. The team recently was awarded $3 million by the National Cancer Institute (NCI). The grant, which began on January 1, 2023, follows previous NCI funding of $2 million that supported laboratory studies yielding fundamental understandings needed to progress to drug development.
The new compounds mimic activity of the sex hormone estrogen on a cell protein called estrogen receptor-beta (ER-beta). This critically important receptor is known to suppress cancer. Both males and females have estrogen, but females have higher levels and it has been noted that more men are diagnosed with GBM than women.
ER-beta may be the answer to treating GBM; it suppresses cancer by activating thousands of genes that collectively have tumor-stunting effects. The small molecule that the San Antonio research team is developing will uniquely bind—or attach to—ER-beta and enhance activation of genes that suppress glioblastoma growth.
UTSA chemists including Stanton McHardy, a professor in the UTSA Department of Chemistry, are working to produce molecules that mimic estrogen activity at ER-beta without the known side effects associated with increased estrogen, such as breast tenderness and vaginal bleeding in women and fatigue and sweating in men.
“My lab will design, synthesize and optimize small-molecule inhibitors of ER-beta,” McHardy said. “Our ultimate goal is to identify a structurally novel ER-beta agonist, a molecule that acts like estrogen, that can be developed clinically.”
McHardy’s involvement in the project is personal. His older sister died of an inoperable GBM tumor for which there were no effective treatments. He says the project has been an extremely efficient and productive collaboration between his laboratory and his research partners.
McHardy is director of the Center for Innovative Drug Discovery (CIDD), a joint initiative of UTSA and UT Health San Antonio that is supported by funding from the Cancer Prevention and Research Institute of Texas (CPRIT). Grants provided by CPRIT were instrumental in offering support for preliminary data generation, which bolstered the team’s NCI-funded proposal.
CIDD is comprised of four collaborating core research facilities: a High-Throughput In Vitro Screening (HTSF) Facility and Computer-Aided Drug Design (CADD) Facility located at UT Health San Antonio and a Medicinal Chemistry Core Facility (MCCF) and a Pre-Clinical Pharmacology Core Facility (PCPC) at UTSA. The center’s mission is to provide a diverse array of core facilities and expertise to facilitate the translation of basic scientific discoveries into tangible pre-clinical candidate drugs that can be later developed into clinical therapies.
Karinel Nieves-Merced and Michael Tidwell, special research associates at CIDD and staff chemists at UTSA, have contributed to the research program. Nieves-Merced assisted in the early compound design stages of the program, and Tidwell synthesized the compounds and characterized their structure.
“This research proposal is based on strong preliminary data showing that ER-beta exerts tumor-suppressive functions in glioblastoma,” said Ratna K. Vadlamudi, professor in the Department of Obstetrics and Gynecology at UT Health San Antonio. “This proposal will develop novel ER-beta drugs that promote tumor suppression, leading to a new therapeutic modality to treat GBM.”
The scientists will go through iterations of ER-beta agonists to develop a novel clinical strategy and bring hope to patients and families affected by GBM. The goal is to move forward with completion of validation using preclinical models and then to test the molecules in clinical trials in two to three years.
“This is a great example of the drug discovery happening here at UTSA that will have real impact on cancer treatment,” said Audrey Lamb, professor and chair of the UTSA Department of Chemistry. “I am very excited by the work Dr. McHardy and his team are doing, which has clear potential for providing a therapeutic strategy in the near future.”
Other researchers who contributed to this study include, from the Department of Obstetrics and Gynecology in the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio: Suryavathi Viswanadhapalli, Ph.D.; Gangadhara R. Sareddy, Ph.D.; Uday P. Pratap, Ph.D. and Rajeshwar Rao Tekmal, Ph.D.; and from the Mays Cancer Center: Andrew Brenner, M.D., Ph.D. and Henriette U. Balinda, Ph.D.
Come celebrate the doctoral students graduating this commencement season.H-E-B Student Union Ballrooms, UTSA Main Campus
Celebrate the accomplishments of the graduates of the College for Health, Community and Policy, College of Liberal and Fine Arts and College of Sciences.Alamodome, 100 Montana St, San Antonio, TX 78203
Celebrate the accomplishments of the graduates of the Carlos Alvarez College of Business, College of Education and Human Development, Margie and Bill Klesse College of Engineering and Integrated Design and University College.Alamodome, 100 Montana St, San Antonio, TX 78203
First Friday Stargazing gives anyone free access to the night sky using university telescopes and teaching equipment. Weather permitting, experienced astronomers will provide a handful of telescopes of varying designs, give training on how each operates, and point to various astronomical objects that may appear in the sky for that given time of the year. If you have a telescope and do not know how to operate it, feel free to bring it and get instructions on its use.4th Floor of Flawn Science Building, Main Campus
The University of Texas at San Antonio is dedicated to the advancement of knowledge through research and discovery, teaching and learning, community engagement and public service. As an institution of access and excellence, UTSA embraces multicultural traditions and serves as a center for intellectual and creative resources as well as a catalyst for socioeconomic development and the commercialization of intellectual property - for Texas, the nation and the world.
To be a premier public research university, providing access to educational excellence and preparing citizen leaders for the global environment.
We encourage an environment of dialogue and discovery, where integrity, excellence, inclusiveness, respect, collaboration and innovation are fostered.
UTSA is a proud Hispanic Serving Institution (HSI) as designated by the U.S. Department of Education.
The University of Texas at San Antonio, a Hispanic Serving Institution situated in a global city that has been a crossroads of peoples and cultures for centuries, values diversity and inclusion in all aspects of university life. As an institution expressly founded to advance the education of Mexican Americans and other underserved communities, our university is committed to ending generations of discrimination and inequity. UTSA, a premier public research university, fosters academic excellence through a community of dialogue, discovery and innovation that embraces the uniqueness of each voice.